Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
What’s Behind the Strong Growth of the Personalized Cell Therapy Market Size in the Last 5 Years?
The market size for personalized cell therapy has seen an impressive surge in growth in the past few years. It is projected to expand from $17.11 billion in 2024 to $20.83 billion in 2025, with a compound annual growth rate (CAGR) of 21.8%.
Factors such as rising consciousness about personalized medicine, growth in healthcare expenditure, augmentation of government initiatives, enhanced funding for clinical studies, and an uptick in neurological disorders can be credited for this historic period growth.
Forecasting for the personalized cell therapy market predicts considerable expansion in the coming years, ballooning to $46.24 billion in 2029 with a compound annual growth rate (CAGR) of 22.1%. This anticipated rise throughout the forecast period is primarily down to increasing clinical trials, growing incidence of chronic diseases, an aging population, rising cancer prevalence, and the escalating adoption of regenerative medicines.
Significant trends expected to impact this period involve technological innovations, incorporation of AI, personalizing vaccines, advancements in bioinformatics, and the application of microfluidic technologies.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Drivers Are Powering the Rise of the Personalized Cell Therapy Market?
The uptick in conditions related to the nervous system is anticipated to augment the expansion of the personalized cell therapy market in the future. Neurological disorders represent a range of diseases impacting the brain, spinal cord, and nerves, resulting in manifestations such as compromised motor ability, cognitive deficiencies, and sensory disruptions.
These disorders result from an aging demographic, environmental pressures, and alterations in lifestyle leading to an increased prevalence of neurodegenerative conditions. Customized cell therapy is essential for these conditions as it provides patient-specific treatments potentially repairing damaged neural tissue and enhancing results in complicated, individualized disorders.
For example, the Parkinson Foundation, a government organization based in the US, indicated that the annual occurrence of Parkinson’s disease (PD) in the elderly is 50% higher than the existing calculation of 60,000 cases in December 2022. Additionally, expectations are that by 2030, an extra 1.2 million Americans will be diagnosed with Parkinson’s disease.
Consequently, the surge in neurological conditions is catalyzing the expansion of the personalized cell therapy market.
How Is the Personalized Cell Therapy Market Structured Across Key Segments?
The personalized cell therapymarket covered in this report is segmented –
1) By Cell Type: Lymphocytes; Mesenchymal Stem Cell; Hematopoietic Stem Cell; Other Cell Type
2) By Technique: Platelet Transfusions; Bone Marrow Transplantation; Packed Red Cell Transfusions; Organ Transplantation
3) By Application: Cardiovascular Diseases; Neurological Disorders; Inflammatory Diseases; Diabetes; Cancer; Other Applications
4) By End-User: Hospital; Homecare; Specialty Clinics; Other End-User
Subsegments:
1) By Lymphocytes: T Cells; Natural Killer (NK) Cells; Regulatory T Cells
2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs; Adipose Tissue-Derived MSCs; Umbilical Cord-Derived MSCs
3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells; Allogeneic Hematopoietic Stem Cells
4) By Other Cell Types: Dendritic Cells; Fibroblasts; Endothelial Cells
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
How Will Market Trends Drive Strategic Shifts in the Personalized Cell Therapy Sector?
Principal corporations in the personalized cell therapy sector are joining forces through strategic alliances to speed up the development and market introduction of cutting-edge treatments. By combining their resources, knowledge, and tools, these companies can improve their research and development endeavors, streamline their clinical experiments, and effectively maneuver through regulatory processes.
For instance, in October 2022, a biotechnology firm based in the US, Century Therapeutics Inc., collaborated with Bristol Myers Squibb (BMS), a US pharmaceutical company, to manufacture and market allogeneic cell therapies. This cooperative venture relies on Century’s breakthrough induced pluripotent stem cell (iPSC) technology to produce engineered natural killer (NK) and T cell treatments designed to combat hematologic malignancies and solid tumors.
The deal covers the creation of up to four distinct cell therapy initiatives, initially concentrating on acute myeloid leukemia (AML) and multiple myeloma. These ventures will leverage engineered NK cells or gamma delta T cells generated from iPSCs.
Where Is the Personalized Cell Therapy Market Experiencing the Fastest Regional Growth?
North America was the largest region in the personalized cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in the personalized cell therapy marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Leading Players Shaping the Future of the Personalized Cell Therapy Industry
Major companies operating in the personalized cell therapy marker are AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Cipla Limited, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd., Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=19137
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
